P. carinii Pneumonia Lung Damage: CD8-driven Cellular and Molecular Events

描述（由申请人提供）：卡氏肺囊虫肺炎（PcP）仍然是艾滋病、癌症、移植受者或其他免疫功能低下疾病患者发病和死亡的重要原因。尽管在医疗实践和有效的抗p。在过去20年里，卡氏杆菌肺炎的发病率和死亡率几乎没有变化，而且仍然高得令人无法接受。总的来说，艾滋病患者的死亡率约为10%/次，非艾滋病患者的死亡率甚至更高，高达40%/次。这可能与这样一个事实有关，即抗生素介导的Pc的有效杀伤并不能立即减少肺中T细胞和Pc抗原同时存在所驱动的PcP的严重免疫病理成分。在过去的9年里，我们已经确定了pc特异性免疫介导的炎症反应在PcP相关肺损伤的免疫发病机制中的作用。具体来说，我们已经证明了CD8+ T细胞在CD4+ T细胞枯竭的宿主中启动这种炎症反应的关键作用。我们的工作假设是，宿主对卡氏疟原虫感染的T细胞介导的免疫反应是PcP发病率和死亡率的主要因素，了解这种损伤如何进展对有效控制这种反应和改善患者预后绝对至关重要。除了靶向T细胞外，我们还确定了T细胞激活下游的特定炎症事件，这些炎症事件可能在ppp相关炎症性肺损伤的产生和持续中起作用。这些事件包括肺泡巨噬细胞（AMs）的激活，TNF-1的产生，以及通过NF-kB和MAPK增强的细胞信号传导。我们的目标是进一步表征PcP期间导致肺损伤的细胞和分子事件，以确定适合治疗干预的特定途径或途径组合。“原理证明”和候选途径在我们的初步研究中已经确定。我们乐观地认为，本文概述的实验将导致NIH路线图中强调的转化临床试验。卡氏杆菌肺炎的发病率和死亡率在过去20年中变化不大，仍然高得令人无法接受。总体而言，艾滋病患者的死亡率约为10%/次，非艾滋病患者的死亡率甚至更高，高达40%/次。本提案中概述的实验旨在导致转化临床试验，旨在改善卡氏杆菌肺炎患者的管理。

DESCRIPTION (provided by applicant): Pneumocystis carinii pneumonia (PcP) continues to be a significant cause of morbidity and mortality among patients with AIDS, cancer, transplant recipients, or other immunocompromising illnesses. Despite the many advances in medical practice and the availability of effective anti-P. carinii antibiotics, the morbidity and mortality due to P. carinii pneumonia has changed little in the last 20 years and remains unacceptably high. Overall, mortality is about 10%/episode in AIDS patients and even higher, up to 40%/episode, in non- AIDS patients. This is likely related to the fact that effective antibiotic-mediated killing of Pc does not immediately reduce the severe immunopathological component of PcP that is driven by the concurrent presence of T cells and Pc antigen in the lung. We have established, over the past 9 years, the role of the Pc-specific immune-mediated inflammatory response in the immunopathogenesis of lung injury associated with PcP. Specifically, we have demonstrated a critical role for CD8+ T cells in the initiation of this inflammatory response in the CD4+ T cell depleted host. Our working hypothesis is that the host's T cell-mediated immune response to infection by P. carinii is a major contributor to the morbidity and mortality of PcP, and that understanding how this injury progresses is absolutely critical to the effective control of this response and improving patient outcomes. In addition to targeting T cells, we have identified specific inflammatory events downstream of T cell activation that may have roles in the generation and persistence of PcP-related inflammatory lung injury. These events include the activation of alveolar macrophages (AMs), the production of TNF-1, and enhanced cell signaling through NF-kB and MAPK. Our goal is to further characterize the cellular and molecular events leading to lung injury during PcP for the purpose of identifying specific pathways or combinations of pathways that lend themselves to therapeutic intervention. "Proof of principle" and candidate pathways have been identified during our initial studies. We are optimistic that the experiments outlined herein will lead to translational clinical trials as emphasized in the NIH roadmap. PUBLIC HEALTH RELEVANCE The morbidity and mortality due to P. carinii pneumonia has changed little in the last 20 years and remains unacceptably high. Overall, mortality is about 10%/episode in AIDS patients and even higher, up to 40%/episode, in non-AIDS patients. The experiments outlined in this proposal are designed to lead to a translational clinical trial designed to improve the management of patients with P. carinii pneumonia.